Skip to content
The Chat Archive
sonar-reasoning LMArena Search Arena 24K

Is NF-kB persistently activated in ovarian cancer patients with drug resistance?

  1. User

    Is NF-kB persistently activated in ovarian cancer patients with drug resistance?

  2. Assistant

    NF-κB is persistently activated in ovarian cancer patients with drug resistance, playing a complex role in promoting chemoresistance and tumor survival. This activation is linked to multiple mechanisms that enhance cancer cell resilience and evade apoptosis.

    Key Findings on NF-κB Activation and Drug Resistance

    1. Association with Poor Prognosis and Resistance

      • High nuclear NF-κB p65 expression correlates with advanced FIGO stage, residual disease, platinum resistance, and poor chemotherapy response in ovarian cancer patients[5].
      • NF-κB activation in aggressive, chemoresistant ovarian cancer cell lines (e.g., SKOV3.ip1, HEYA8) promotes tumor growth and survival, unlike its tumor-suppressive role in non-resistant parental lines[1][2].
    2. Mechanisms of Chemoresistance

      • NF-κB inhibits apoptosis by regulating MAPK phosphorylation and upregulating anti-apoptotic genes[1][7].
      • It enhances cancer stem cell maintenance, metastasis, and immune evasion, contributing to recurrent disease[2][8].
      • Cisplatin and other chemotherapies can paradoxically activate NF-κB, leading to self-induced resistance[7][8].
    3. Clinical and Experimental Evidence

      • Nuclear accumulation of NF-κB p65 in epithelial ovarian cancer tissue predicts longer survival in chemotherapy-responsive patients but is associated with resistance in aggressive variants[1][5].
      • Inhibiting NF-κB in resistant cell lines restores cisplatin sensitivity and reduces tumor growth in vivo[1][5].

    Therapeutic Implications

    Targeting NF-κB signaling shows promise for overcoming resistance, but challenges remain due to its dual roles in normal and cancer cells. Strategies include selective inhibition in tumor-initiating cells or combining NF-κB blockers with immunotherapy[2][7].

    In summary, persistent NF-κB activation is a hallmark of drug-resistant ovarian cancer, driven by its role in survival pathways and adaptive responses to chemotherapy. Clinical studies confirm its prognostic and therapeutic relevance[1][5][7].

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.

Identical first prompt